338454-98-1

Basic information

• Product Name: 4-(4-Bromo-2-fluorobenzyl)morpholine
• Synonyms: 4-(4-Bromo-2-fluorobenzyl)morpholine
• CAS NO: 338454-98-1
• Molecular Formula: C₁₁H₁₃BrFNO
• Molecular Weight: 274.1294232
• Product Categories: alkyl bromide|alkyl Fluorine
• Mol File: 338454-98-1.mol

Chemical Properties

• Appearance: /Solid
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-(4-Bromo-2-fluorobenzyl)morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Bromo-2-fluorobenzyl)morpholine(338454-98-1)
• EPA Substance Registry System: 4-(4-Bromo-2-fluorobenzyl)morpholine(338454-98-1)

Safety Data

• Hazardous Substances Data: 338454-98-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-Bromo-2-fluorobenzyl)morpholine is used as a building block for the synthesis of various pharmaceutical products due to its potential antiviral, antifungal, and antibacterial properties. Its unique structure allows it to be incorporated into the development of new drugs with enhanced therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical industry, 4-(4-Bromo-2-fluorobenzyl)morpholine is utilized as a key component in the creation of agrochemical products. Its potential biological activity contributes to the development of effective pesticides and other agricultural chemicals.
Used in Metal-Catalyzed Reactions:
4-(4-Bromo-2-fluorobenzyl)morpholine is employed as a ligand in metal-catalyzed reactions. Its presence can enhance the efficiency and selectivity of these reactions, leading to improved synthetic routes and the production of desired compounds.
Used in Organic Synthesis:
As a precursor in organic synthesis, 4-(4-Bromo-2-fluorobenzyl)morpholine plays a crucial role in the formation of complex organic molecules. Its reactivity and structural features enable the synthesis of a wide range of compounds with diverse applications in various industries.

Upstream product

• 110-91-8 morpholine 
• 76283-09-5 4-bromo-2-fluorobenzyl bromide 
• 51436-99-8 2-fluoro-4-bromotoluene 
• 57848-46-1 4-bromo-2-fluorobenzaldehyde 

Downstream Products

• 1073354-74-1 4-{[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl}morpholine 
• 933986-53-9 (E)-4-(2-fluoro-4-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)vinyl)benzyl)morpholine 

Relevant articles and documents

TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS

Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.

Novel Triazolopyrazine Derivatives and Use Thereof

The present invention relates to novel triazolopyrazine derivatives or a pharmaceutically acceptable salt, and a pharmaceutical composition for inhibiting c-Met tyrosine kinase activity and a pharmaceutical composition for preventing or treating hyperproliferative disorders, containing the same as active ingredients. The present invention effectively inhibits c-Met tyrosine kinase activity, thereby being able to be useful as a drug for various hyperproliferative disorders such as cancers, psoriasis, rheumatoid arthritis, diabetic retinitis, etc. related to excessive cell proliferation and growth by abnormal kinase activation.

Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy

The antiplasmodial activity, DMPK properties, and efficacy of a series of quinoline-4-carboxamides are described. This series was identified from a phenotypic screen against the blood stage of Plasmodium falciparum (3D7) and displayed moderate potency but with suboptimal physicochemical properties and poor microsomal stability. The screening hit (1, EC50 = 120 nM) was optimized to lead molecules with low nanomolar in vitro potency. Improvement of the pharmacokinetic profile led to several compounds showing excellent oral efficacy in the P. berghei malaria mouse model with ED90 values below 1 mg/kg when dosed orally for 4 days. The favorable potency, selectivity, DMPK properties, and efficacy coupled with a novel mechanism of action, inhibition of translation elongation factor 2 (PfEF2), led to progression of 2 (DDD107498) to preclinical development.

NOVEL TRIAZOLOPYRAZINE DERIVATIVE AND USE THEREOF

The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating hyper proliferative disorder. The present invention can be useful as a therapeutic agent for various hyper proliferative disorders associated with excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy, by efficiently inhibiting c-Met tyrosine kinase activity.

Anti-Malarial Agents

The present invention relates to a novel class of quinolone-4-carboxamide Pf3D7 inhibitors of general formula (I) (Formula (I)) wherein R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein, to their use in medicine, and in the treatment of malaria in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.

ANTI-MALARIAL AGENTS

The present invention relates to a novel class of quinolone-4-carboxamide Pf3D7 inhibitors of general formula (I) (Formula (I)) wherein R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein, to their use in medicine, and in the treatment of malaria in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.

[1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS

Novel [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a Formula represented by the following: (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, joint disease, inflammation, and others.